Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: The brain and the vessels

Gynecological Endocrinology

Volumn 23, Issue SUPPL. 1, 2007, Pages 9-16

  Simoncini, Tommaso ^a   Mannella, Paolo ^a   Pluchino, Nicola ^a   Genazzani, Andrea R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cardiovascular system; Central nervous system; Dydrogesterone; Hormone replacement therapy; Progestins

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; 4 AMINOBUTYRIC ACID A RECEPTOR; BETA ENDORPHIN; CONJUGATED ESTROGEN; CORTICOTROPIN RELEASING FACTOR; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DYDROGESTERONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTRADIOL BENZOATE; ESTRADIOL VALERATE; ESTRONE SULFATE; GESTAGEN; GESTODENE; GLUCOCORTICOID; GONADORELIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NORETHISTERONE ACETATE; NORGESTIMATE; PROGESTERONE; PROOPIOMELANOCORTIN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; UNINDEXED DRUG;

ATHEROGENESIS; BRAIN LEVEL; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DRUG EFFECT; DRUG POTENTIATION; ENDOMETRIUM; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; EXPERIMENTAL MODEL; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MONOTHERAPY; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE METABOLISM; PROGESTERONE SYNTHESIS; RISK ASSESSMENT; RISK REDUCTION; TESTOSTERONE METABOLISM; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DYDROGESTERONE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; PROGESTERONE CONGENERS;

EID: 35349027687     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701585094     Document Type: Conference Paper

References (83)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
2. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, et al. The Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-613.
4. Genazzani AR, Gambacciani M, Simoncini T. Estrogens and women's health: a scary or a fairy tale? Gynecol Endocrinol 2004;18:175-178.
5. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-1712.
6. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997;3:324-327.
7. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998;18:1164-1171.
8. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-bestradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-1057.
9. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154-2159.
10. Wang MD, Wahlstrom G, Backstrom T. The regional brain distribution of the neurosteroids pregnenolone and pregnenolone sulfate following intravenous infusion. J Steroid Biochem Mol Biol 1997;62:299-306.
11. Stoffel-Wagner B, Watzka M, Schramm J, Bidlingmaier F, Klingmuller D. Expression of CYP19 (aromatase) mRNA in different areas of the human brain. J Steroid Biochem Mol Biol 1999;70:237-241.
12. Baulieu EE. Neurosteroids: a new function in the brain. Biol Cell 1991;71:3-10.
13. Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 1997;52:1-32.
14. Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendorfer RA, Pirke KM, Kirschbaum C. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2363-2367.
15. Schumacher M, Coirini H, McEwen BS. Regulation of high-affinity GABAA receptors in the dorsal hippocampus by estradiol and progesterone. Brain Res 1989;487:178-183.
16. Palumbo MA, Salvestroni C, Gallo R, Guo AL, Genazzani AD, Artini PG, Petraglia F, Genazzani AR. Allopregnanolone concentration in hippocampus of prepubertal rats and female rats throughout estrous cycle. J Endocrinol Invest 1995;18:853-856.
17. Genazzani AR, Bernardi F, Stomati M, Monteleone P, Luisi S, Rubino S, Farzati A, Casarosa E, Luisi M, Petraglia F. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Neuroendocrinology 2000;72:162-170.
18. Genazzani AR, Palumbo MA, de Micheroux AA, Artini PG, Criscuolo M, Ficarra G, Guo AL, Benelli A, Bertolini A, Petraglia F, et al. Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats. Eur J Endocrinol 1995;133:375-380.
19. Stomati M, Bernardi F, Luisi S, Puccetti S, Casarosa E, Liut M, Quirici B, Pieri M, Genazzani AD, Luisi M, et al. Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and β-endorphin. Maturitas 2002;43:195-206.
20. Genazzani AR, Stomati M, Bernardi F, Luisi S, Casarosa E, Puccetti S, Genazzani AD, Palumbo M, Luisi M. Conjugated equine estrogens reverse the effects of aging on central and peripheral allopregnanolone and β-endorphin levels in female rats. Fertil Steril 2004;81(Suppl 1):757-766.
21. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171-177.
22. Bitran D, Purdy RH, Kellogg CK. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol Biochem Behav 1993;45:423-428.
23. Frye CA, Bayon LE, Pursnani NK, Purdy RH. The neurosteroids, progesterone and 3α,5α-THP, enhance sexual motivation, receptivity, and proceptivity in female rats. Brain Res 1998;808:72-83.
24. Corpechot C, Young J, Calvel M, Wehrey C, Veltz JN, Touyer G, Mouren M, Prasad VV, Banner C, Sjovall J, et al. Neurosteroids: 3α-hydroxy-5α- pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology 1993;133:1003-1009.
25. Bernardi F, Pluchino N, Pieri M, Begliuomini S, Lenzi E, Puccetti S, Casarosa E, Luisi M, Genazzani AR. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and β-endorphin levels. Neuroendocrinology 2006;83:348-359.
26. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000;14:223-230.
27. Labrie F, Lagacè L, Drouin J. Direct and differential effects of sex steroids at the anterior pituitary level on LH and FSH secretion. London: Academic Press; 1979.
28. Etgen AM, Karkanias GB. Estrogen regulation of noradrenergic signaling in the hypothalamus. Psychoneuroendocrinology 1994;19:603-610.
29. Genazzani AR, Petraglia F, Facchinetti F, Grasso A, Alessandrini G, Volpe A. Steroid replacement treatment increases β-endorphin and β-lipotropin plasma levels in postmenopausal women. Gynecol Obstet Invest 1988;26:153-159.
30. Genazzani AR, Petraglia F, Facchinetti F, Facchini V, Volpe A, Alessandrini G. Increase of proopiomelanocortin-related peptides during subjective menopausal flushes. Am J Obstet Gynecol 1984;149:775-779.
31. Aleem FA, McIntosh TK. Menopausal syndrome: plasma levels of β-endorphin in post-menopausal women measured by a specific radioimmunoassay. Maturitas 1985;7:329-334.
32. Piva F, Limonta P, Dondi D, Pimpinelli F, Martini L, Maggi R. Effects of steroids on the brain opioid system. J Steroid Biochem Mol Biol 1995;53:343-348.
33. Wardlaw SL, Wehrenberg WB, Ferin M, Antunes JL, Frantz AG. Effect of sex steroids on β-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 1982;55:877-881.
34. Fox SR, Harlan RE, Shivers BD, Pfaff DW. Chemical characterization of neuroendocrine targets for progesterone in the female rat brain and pituitary. Neuroendocrinology 1990;51:276-283.
35. Dufourny L, Caraty A, Clarke IJ, Robinson JE, Skinner DC. Progesterone-receptive β-endorphin and dynorphin B neurons in the arcuate nucleus project to regions of high gonadotropinreleasing hormone neuron density in the ovine preoptic area. Neuroendocrinology 2005;81:139-149.
36. Genazzani AR, Petraglia F, Bergamaschi M, Genazzani AD, Facchinetti F, Volpe A. Progesterone and progestins modulate β-endorphin concentrations in the hypothalamus and in the pituitary of castrated female rats. Gynecol Endocrinol 1987;1:61-69.
37. Szot P, Wilkinson CW, White SS, Leverenz JB, Greenup JL, Colasurdo EA, Peskind ER, Raskind MA. Chronic cortisol suppresses pituitary and hypothalamic peptide message expression in pigtailed macaques. Neuroscience 2004;126:241-246.
38. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988;11:308-314.
39. La Vecchia C, Decarli A, Franceschi S, Gentile A, Negri E, Parazzini F. Menstrual and reproductive factors and the risk of myocardial infarction in women under fifty-five years of age. Am J Obstet Gynecol 1987;157:1108-1112.
40. Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997;82:3913-3918.
41. Herrington DM, Howard TD. From presumed benefit to potential harm - hormone therapy and heart disease. N Engl J Med 2003;349:519-521.
42. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
43. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, et al., for the Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med 2006;166:357-365.
44. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
45. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
46. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kishimoto T, Kasayama S. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001;21:243-248.
47. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR. In vitro effects of progesterone and progestins on vascular cells. Steroids 2003;68:831-836.
48. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, Baldacci C, Genazzani AR. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745-5756.
49. Liao JK. Endothelial nitric oxide and vascular inflammation. In: Panza JA, Cannon ROI, editors. Endothelium, nitric oxide and atherosclerosis. Armonk (NY): Futura Publishing Co. Inc; 1999. pp 119-132.
50. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998;31:582-588.
51. Nilsen J, Brinton RD. Impact of progestins on estradiolpotentiation of the glutamate calcium response. Neuroreport 2002;13:825-830.
52. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A 2003;100:10506-10511.
53. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003;148:281-292.
54. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-758.
55. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-541.
56. Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-479.
57. Simoncini T, Rabkin E, Liao JK. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:198-203.
58. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003;144:3449-3455.
59. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-259.
60. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865-883.
61. Hague S, MacKenzie IZ, Bicknell R, Rees MC. In-vivo angiogenesis and progestogens. Hum Reprod 2002;17:786-793.
62. Paris JM, Williams KJ, Hermsmeyer KR, Delansorne R. Nomegestrol acetate and vascular reactivity: nonhuman primate experiments. Steroids 2000;65:621-627.
63. Williams JK, Delansorne R, Paris J. Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys. J Steroid Biochem Mol Biol 1998;65:219-224.
64. Sorensen MB, Collins P, Ong PJL, Webb CM, Hayward CS, Asbury EA, Gatehouse PD, Elkington AG, Yang GZ, Kubba A, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002;106:1646-1651.
65. Koh KK, Jin DK, Yang SH, Lee SK, Hwang HY, Kang MH, Kim W, Kim DS, Choi IS, Shin EK. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-1966.
66. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 2002;33:1685-1691.
67. Dinh H, Nathan L. Medroxyprogesterone acetate does not antagonize estrogen-induced increases in endothelium-dependent vasodilation: potential clinical implications. Fertil Steril 2002;78:122-127.
68. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-283.
69. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem 1995;270:15320-15326.
70. Garcia-Segura LM, Cardona-Gomez P, Naftolin F, Chowen JA. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport 1998;9:593-597.
71. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002;23:665-686.
72. McDonnell DP. Mining the complexities of the estrogen signaling pathways for novel therapeutics. Endocrinology 2003;144:4237-4240.
73. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW. Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 2003;23:3763-3773.
74. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15.
75. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3-63.
76. Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T, Golan DE. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1999;96:2788-2793.
77. Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, Serra GB, Genazzani AR. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas 2002;41:299-311.
78. Mijatovic V, Kenemans P, Netelenbos JC, Peters-Muller ER, van Kamp GJ, Voetberg GA, van de Weijer PH, van der Mooren MJ. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 1997;82:3543-3547.
79. Mijatovic V, Kenemans P, Netelenbos C, Jakobs C, Popp-Snijders C, Peters-Muller ER, van der Mooren MJ. Postmenopausal oral 17β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998;69:876-882.
80. Godsland IF, Crook D, Proudler AJ, Stevenson JC. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 2005;90:190-197.
81. Gaspard UJ, Wery OJ, Scheen AJ, Jaminet C, Lefebvre PJ. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric 1999;2:93-100.
82. de Kraker AT, Kenemans P, Smolders RG, Kroeks MV, van der Mooren MJ. The effects of 17β-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 2004;49:253-263.
83. Simoncini T, Caruso A, Giretti MS, Scorticati C, Fu XD, Garibaldi S, Baldacci C, Mannella P, Fornari L, Genazzani AR. Effects of dydrogesterone and of its stable metabolite, 20α-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006;86(Suppl 4):1235-1242.